Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer

This study has been completed.
Information provided by:
National University Hospital, Singapore Identifier:
First received: May 24, 2010
Last updated: December 10, 2013
Last verified: December 2013

The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a biomarker in cancer.

Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a useful biomarker to distinguish between malignant and non-malignant causes of pleural effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to diagnose cancer or monitor the treatment progress of cancer.

Condition Intervention
Other: Pyruvate kinase isoform M2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by National University Hospital, Singapore:

Study Start Date: April 2010
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Cancer patient Other: Pyruvate kinase isoform M2


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Any cancer patient


Inclusion Criteria:

  • Any cancer patient with pleural effusion that is being drained through an indwelling chest-tube in an inpatient ward.

Exclusion Criteria:

  • Patient with a pleural effusion who does not have proven cancer or whose pleural effusion is not known to be malignant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01130584

National University Hospital, Singapore
Singapore, Singapore
Sponsors and Collaborators
National University Hospital, Singapore
  More Information

Publications: Identifier: NCT01130584     History of Changes
Other Study ID Numbers: PK01/02/10
Study First Received: May 24, 2010
Last Updated: December 10, 2013
Health Authority: Singapore: Domain Specific Review Boards

Keywords provided by National University Hospital, Singapore:
Cancer Patients processed this record on November 25, 2014